Sobi opens European and Benelux office in Brussels

Today Sobi (Swedish Orphan Biovitrum AB (publ)) formally opened its new European and Benelux office in Brussels, Belgium. The inauguration, celebrated today with a ribbon-cutting ceremony, results from Sobi's expanding international presence and further strengthens the company's platform in Europe as well as in the Benelux Region.

"Brussels provides an ideal location for our European operations", said Hege Hellstrom, President EMENAR at Sobi. "Being a company dedicated to rare diseases, Brussels is of vital importance to Sobi from a business, regulatory, policy and stakeholder interaction perspective. The Belgian authorities have also consistently been thought leaders in collaborative, cross-border approaches to access and availability of rare disease therapies for patients."

The Brussels office will act as an operational hub for Sobi's business and is consistent with the strategic importance of Europe for Sobi, representing approximately 60 per cent of the company's global annual product sales. The office will also enable additional focus on the business in the Benelux region.

The opening of the new office in Brussels is a next step in Sobi's mission to develop and deliver innovative therapies and services to improve the lives of patients living with rare diseases. With more than 600 employees and offices in 24 different countries, Sobi currently delivers therapies to patients in 67 countries across the globe. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases, and two of the company's Haemophilia treatments in development are currently being reviewed by the European Medicines Agency.

- - -

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (€265 M) and about 600 employees. The share (STO: SOBI) is listed on Nasdaq OMX Stockholm. More information is available at www.sobi.com.

For more information please contact:

Corporate media relations                                                                        
Oskar Bosson, Head of Communications                                                  
T:+46 704 107 180
oskar.bosson@sobi.com

Regional Contact
Hege Hellstrom, President EMENAR                           
T: +32 473 888 488
hege.hellstrom@sobi.com

Country Contact
Karel Fol, Country Manager Benelux
T: +32 475 555 775
Karel.fol@sobi.com